These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 32783247)

  • 1. Tannins inhibit SARS-CoV-2 through binding with catalytic dyad residues of 3CL
    Khalifa I; Zhu W; Mohammed HHH; Dutta K; Li C
    J Food Biochem; 2020 Oct; 44(10):e13432. PubMed ID: 32783247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyacylated anthocyanins constructively network with catalytic dyad residues of 3CL
    Khalifa I; Nawaz A; Sobhy R; Althwab SA; Barakat H
    J Mol Graph Model; 2020 Nov; 100():107690. PubMed ID: 32745925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CL
    Gyebi GA; Ogunro OB; Adegunloye AP; Ogunyemi OM; Afolabi SO
    J Biomol Struct Dyn; 2021 Jun; 39(9):3396-3408. PubMed ID: 32367767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting natural products against SARS-CoV-2.
    Al-Harrasi A; Behl T; Upadhyay T; Chigurupati S; Bhatt S; Sehgal A; Bhatia S; Singh S; Sharma N; Vijayabalan S; Palanimuthu VR; Das S; Kaur R; Aleya L; Bungau S
    Environ Sci Pollut Res Int; 2022 Jun; 29(28):42404-42432. PubMed ID: 35362883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL
    Liu WS; Li HG; Ding CH; Zhang HX; Wang RR; Li JQ
    Aging (Albany NY); 2021 Mar; 13(5):6258-6272. PubMed ID: 33678621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.
    Ahmad B; Batool M; Ain QU; Kim MS; Choi S
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Phytochemicals from Arabian Peninsula Medicinal Plants as Strong Binders to SARS-CoV-2 Proteases (3CL
    Saquib Q; Bakheit AH; Ahmed S; Ansari SM; Al-Salem AM; Al-Khedhairy AA
    Molecules; 2024 Feb; 29(5):. PubMed ID: 38474509
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural basis of SARS-CoV-2 3CL
    Tahir Ul Qamar M; Alqahtani SM; Alamri MA; Chen LL
    J Pharm Anal; 2020 Aug; 10(4):313-319. PubMed ID: 32296570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2.
    Olubiyi OO; Olagunju M; Keutmann M; Loschwitz J; Strodel B
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32668701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study on the mechanism of active components of Liupao tea on 3CL
    Ni WJ; Chen XX; Wei SY; Lan LL; Qiu RJ; Ling YP; Zhou DS; Wu ZM; Cao ZH; Yu CP; Zeng Y
    J Food Biochem; 2021 May; 45(5):e13707. PubMed ID: 33760271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral phytocompounds "ellagic acid" and "(+)-sesamin" of
    Umar AK; Zothantluanga JH; Aswin K; Maulana S; Sulaiman Zubair M; Lalhlenmawia H; Rudrapal M; Chetia D
    Struct Chem; 2022; 33(5):1445-1465. PubMed ID: 35571865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Room-temperature X-ray crystallography reveals the oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL M
    Kneller DW; Phillips G; O'Neill HM; Tan K; Joachimiak A; Coates L; Kovalevsky A
    IUCrJ; 2020 Sep; 7(Pt 6):1028-35. PubMed ID: 33063790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 9,10-dihydrophenanthrene derivatives as SARS-CoV-2 3CL
    Zhang JW; Xiong Y; Wang F; Zhang FM; Yang X; Lin GQ; Tian P; Ge G; Gao D
    Eur J Med Chem; 2022 Jan; 228():114030. PubMed ID: 34883292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of quenched fluorescent peptide substrates of SARS-CoV-2 3CL
    Cesar Ramos de Jesus H; Solis N; Machado Y; Pablos I; Bell PA; Kappelhoff R; Grin PM; Sorgi CA; Butler GS; Overall CM
    J Virol; 2024 Jun; 98(6):e0004924. PubMed ID: 38742901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An
    Mishra B; Ballaney P; Saha G; Shinde A; Banerjee S; Thimmakondu VS; Aduri R
    J Biomol Struct Dyn; 2023 May; 41(8):3167-3186. PubMed ID: 35261325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
    Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
    Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay.
    Loschwitz J; Jäckering A; Keutmann M; Olagunju M; Eberle RJ; Coronado MA; Olubiyi OO; Strodel B
    Bioorg Chem; 2021 Jun; 111():104862. PubMed ID: 33862474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Catalytic Dyad Residues His41 and Cys145 Impact the Catalytic Activity and Overall Conformational Fold of the Main SARS-CoV-2 Protease 3-Chymotrypsin-Like Protease.
    Ferreira JC; Fadl S; Villanueva AJ; Rabeh WM
    Front Chem; 2021; 9():692168. PubMed ID: 34249864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Docking and Dynamics Investigations for Identifying Potential Inhibitors of the 3-Chymotrypsin-like Protease of SARS-CoV-2: Repurposing of Approved Pyrimidonic Pharmaceuticals for COVID-19 Treatment.
    Elzupir AO
    Molecules; 2021 Dec; 26(24):. PubMed ID: 34946540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.